New Biosimilar Approval Pathway Creates Device Opportunities
This article was originally published in The Pink Sheet Daily
Several companies focusing on specialized injectors designed to improve patient comfort and compliance say their technologies will be crucial to differentiating biopharmaceutical products that are vying for the same patient population, but contain virtually the same active ingredient.
You may also be interested in...
In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.
Human factors engineering has gained traction in the device industry in recent years, but Richmond-based Intelliject is a rare example of a firm trying to build a business around a focus on product usability
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.